Cayman Chemical Company Incorporated

Myometrics LLC

University of Michigan

Fred Lawrence Ciske

Stephen Douglas Barrett

Gregory William Endres

James Bernard Kramer

Adam Uzieblo

Bradlee David Germain

Joseph Michael Colombo

Andriy Kornilov

Kirk M Maxey

Thomas Allen Owen

James Paul O'Malley

Kirk Lang Olson

Andriy Komilov

Pil Heui Lee

Raymond C Trievel

Jeffrey Keith Johnson

Levi Lynn Blazer

Daniel Austin Bochar

Gregory Scott Keyes

Ranjinder Singh Sidhu

Margaret Lynn Collins

James Paul O'malley

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Methods, systems, and compositions for promoting bone growth

Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compounds of formula (I) wherein L, L, L, R, R, R, and Rare as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

Difluorolactam compositions for EP4-mediated osteo related diseases and conditions

Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin Dmediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).

Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM -utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding.

Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins

Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

Growing community of inventors

Dexter, MI, United States of America

Fred Lawrence Ciske